FDA Inspection 1223321 — InvaGen Pharmaceuticals, Inc.

InvaGen Pharmaceuticals, Inc. — FEI 3003950641

The FDA completed an inspection of InvaGen Pharmaceuticals, Inc. on October 25, 2023 in Hauppauge, NY. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
October 25, 2023
Fiscal Year
2024
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Hauppauge, NY (United States)